Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca settles with Teva over Nexium

AstraZeneca has reached an agreement with Teva Pharmacueticals regarding patent infringement on heartburn drug, Nexium

AstraZeneca (AZ) has announced it has reached an agreement with Teva Pharmaceuticals regarding the Israeli firm's proposed generic version of AZ's heartburn drug, Nexium, which AZ claim would have infringed the Anglo-Swedish firm's patent.

Under the agreement, AZ has granted Teva a license to enter the US market with its generic esomeprazole when the first Nexium patent expires on 27 May 2014, subject to regulatory approval, or earlier in certain circumstances.

Teva, the world's biggest generic drug maker, accepted that all patents-at-issue in the litigations are valid and enforceable, and conceded that six Nexium patents would be infringed by the manufacture on sale of esomeprazole. With this the US District Court for the District of New Jersey will enter a Consent Judgment and corresponding Nexium patent litigations will be dismissed/

The deal further protects AZ's top-selling drug from generic competition following a 2008 out-of-court settlement with Indian company, Ranbaxy Laboratories, who also conceded to patent infringement. Like Teva, their generic version of Nexium is being held back until 2014.

In a separate agreement, AZ and Teva have agreed to settle patent litigation related to Prilosec (omeprazole). This settlement will see a one-time payment to AZ to cover past infringing sales, though AZ have described the terms of the agreement as "not financially material".

News of the settlements has seen AstraZeneca's shares increase by 1.4% as Teva's fell by 0.2% (both details as of 9.32am GMT, Thursday January 7.)

A further patent dispute regarding Nexium with Indian firm, Dr Reddy's Laboratories is still to be settled. 

7th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics